RA patients characterized by elevated sAPRIL and sBCMA levels exhibited a higher prevalence of autoantibodies, increased type I IFN activation and elevated levels of proinflammatory and immune-stimulatory mediators despite being largely treated with anti-TNFα agents. This evidence concerns the gene TNF and rheumatoid arthritis.